Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs GeneDx Holdings Corp — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.75 (market cap $141.25M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 14.3× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 5,492,367). Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and GeneDx Holdings Corp for 19 Days on average.
| KOLD | WGS | |
|---|---|---|
Market Cap | $141.25M | $2.02B |
Volume | 5,492,367 | 734,640 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $167.51 |
52-Week Low | $13.58 | $34.51 |
Typical Hold Time | 10 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $25.68, up 3.38% today, but faces bearish technical signals with 15 sell indicators versus 2 buy signals. The stock is trading near its pivot point of $25 with immediate resistance at $26 and support at $25. Recent news highlights volatility in natural gas markets with record production levels and geopolitical tensions affecting energy sector sentiment.
The outlook remains cautious with strong bearish momentum indicators and fundamental data gaps. Investment opportunity exists for contrarian traders near support levels, but risks include energy price volatility and production oversupply concerns. Technical weakness suggests potential for further downside testing of $24-$25 support zone.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
